Reata Pharmaceuticals Inc. Class A (RETA) Peer Comparison
$172.36
$0.00 (0.00%)As on 26-Sep-2023 09:30EDT
Market cap
$6,566 Mln
Revenue (TTM)
$24 Mln
P/E Ratio
--
P/B Ratio
285.9
Div. Yield
0 %
Edit
| Reata Pharmaceuticals Inc. Class A (RETA) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
6,566 | 16,765 | 13,492 | 12,332 | 11,994 |
Revenue ($ Mln) |
24 | 2,782 | 2,436 | 1,284 | 670 |
Net Profit ($ Mln) |
-80.06 | 491.50 | 860.62 | -325.10 | -319.95 |
Net Margin (%) |
-1,913.41 | 17.67 | 35.33 | -25.32 | -47.79 |
RoE (%) |
-- | 110.09 | 42.98 | -57.72 | -71.14 |
Price to Earnings |
-- | 35.25 | 17.40 | -- | -- |
Price-To-Book |
285.94 | 39.29 | 7.42 | 23.98 | 26.87 |
Income Statement ($ Mln)
| Reata Pharmaceuticals Inc. Class A (RETA) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
24.40 | 1,460.00 | 1,611.06 | 0.00 | 243.23 |
|
Cost of Revenue
|
0.85 | 1,027.56 | 57.91 | 0.47 | 10.42 |
|
Gross Profit
|
2.22 | 432.44 | 1,553.15 | 0.00 | 243.23 |
|
Operating Expenses
|
364.30 | 153.74 | 1,351.67 | 293.57 | 421.74 |
|
Operating Profit (EBIT)
|
-59.48 | 278.70 | 201.48 | -293.57 | -178.51 |
|
Other Income
|
-20.21 | 7.07 | -0.20 | 2.19 | 0.77 |
|
Profit before Tax
|
-87.68 | 282.86 | 234.35 | -295.35 | -172.71 |
|
Provision for Tax
|
0.25 | 37.49 | 52.07 | 3.96 | 3.79 |
|
Profit after Tax (Net Income)
|
-80.06 | 245.37 | 182.28 | -295.35 | -176.49 |
|
Minority Interest
|
0.00 | -- | -- | -- | 19.82 |
|
Consolidated Profit
|
-280.62 | 245.37 | 182.28 | -295.35 | -176.06 |
Liabilities ($ Mln)
| Reata Pharmaceuticals Inc. Class A (RETA) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
87.29 | 386.39 | 2,488.43 | 197.39 | 398.52 |
|
Minority Interest
|
0.00 | -- | -- | -- | 19.82 |
|
Non-Current Liabilities
|
290.20 | 162.64 | 258.70 | 49.29 | 134.75 |
|
Current Liabilities
|
125.09 | 803.47 | 324.36 | 115.89 | 138.85 |
|
Total Liabilities
|
514.49 | 1,352.50 | 3,071.49 | 362.57 | 691.94 |
Assets ($ Mln)
| Reata Pharmaceuticals Inc. Class A (RETA) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
100.74 | 1,018.53 | 1,452.73 | 1.20 | 286.64 |
|
Current Assets
|
401.85 | 333.96 | 1,618.76 | 361.37 | 405.30 |
|
Total Assets
|
514.49 | 1,352.50 | 3,071.49 | 362.57 | 691.94 |
|
Total Debt*
|
166.00 | 188.87 | 190.17 | 49.89 | 81.58 |
|
Net Current Assets
|
276.76 | -469.51 | 1,294.40 | 245.48 | 302.30 |
Cashflow ($ Mln)
| Reata Pharmaceuticals Inc. Class A (RETA) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-204.27 | 388.05 | 362.61 | -224.86 | -136.13 |
|
Cash Flow from Investing Activities
|
-345.16 | -38.74 | -524.41 | 206.69 | -5.42 |
|
Cash from Financing Activities
|
1.49 | -775.78 | 0.59 | 313.45 | 65.19 |
|
Net Cash Inflow / Outflow
|
-547.95 | -426.47 | -161.21 | 295.28 | -76.36 |
Ratios
Profitability Ratios
| Reata Pharmaceuticals Inc. Class A (RETA) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
58.53 | 29.58 | 7.38 | -132.99 | -38.60 |
|
ROE (%)
|
47.21 | 36.64 | 7.76 | -150.12 | -43.72 |
|
ROA (%)
|
-12.26 | 16.29 | 6.41 | -92.89 | -25.18 |
|
EBIT Margin (%)
|
-1,368.23 | -- | -- | -- | -- |
|
Net Margin (%)
|
-1,913.41 | 16.73 | 11.32 | -13,517.16 | -72.33 |
|
Cash Profit Margin (%)
|
0.00 | -- | -- | -- | -- |
Growth Ratios
| Reata Pharmaceuticals Inc. Class A (RETA) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
143.93 | 0.28 | 0.12 | -- | 0.76 |
|
EBIT Growth (%)
|
-29.51 | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
73.72 | 34.93 | -21.11 | -22.51 | -25.31 |
|
EPS Growth (%)
|
66.48 | 0.57 | -0.21 | -0.21 | -0.24 |
|
Book Value Growth (%)
|
105.47 | -- | -- | -- | -- |
Valuation Ratios
| Reata Pharmaceuticals Inc. Class A (RETA) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-4.42 | 28.07 | 28.45 | -16.94 | -19.80 |
|
Price / Book Value
|
-21.00 | 17.82 | 2.08 | 25.35 | 8.77 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-4.13 | 22.87 | 18.29 | -16.14 | -19.04 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Reata Pharmaceuticals Inc. Class A (RETA) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.84 | 0.49 | 0.08 | 0.25 | 0.20 |
|
Short term debt to equity ratio
|
0.03 | 0.13 | 0.01 | 0.00 | 0.01 |
|
Current Ratio
|
3.21 | 0.42 | 4.99 | 3.12 | 2.92 |
|
Quick Ratio
|
3.19 | -- | 4.89 | -- | 3.07 |
|
Interest Coverage
|
-1.16 | 98.37 | 3.75 | -73.51 | -35.47 |
Operating Efficiency Ratios
| Reata Pharmaceuticals Inc. Class A (RETA) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
92.90 | 17.36 | 13.33 | -- | 0.58 |
|
Asset Turnover
|
0.04 | 0.97 | 0.57 | 0.00 | 0.35 |
|
Receivable days
|
-- | 55.02 | 56.39 | -- | 8.76 |
|
Inventory Days
|
-- | -- | 191.72 | -- | -302.34 |
|
Payable days
|
-- | 10.44 | 179.52 | 17,680.21 | 215.99 |
|
Cash Conversion Cycle
|
-- | -- | 68.58 | -- | -509.57 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
